

# Samuel L Washington Iii

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3577058/publications.pdf>

Version: 2024-02-01

97  
papers

998  
citations

516215

16  
h-index

500791

28  
g-index

106  
all docs

106  
docs citations

106  
times ranked

1504  
citing authors

#	ARTICLE	IF	CITATIONS
1	Rapid Utilization of Telehealth in a Comprehensive Cancer Center as a Response to COVID-19: Cross-Sectional Analysis. <i>Journal of Medical Internet Research</i> , 2020, 22, e19322.	2.1	127
2	Out-of-Pocket Fertility Patient Expense: Data from a Multicenter Prospective Infertility Cohort. <i>Journal of Urology</i> , 2014, 191, 427-432.	0.2	105
3	Impact of the United States Preventive Services Task Force "D"™ recommendation on prostate cancer screening and staging. <i>Current Opinion in Urology</i> , 2017, 27, 205-209.	0.9	45
4	Transrectal ultrasonography-guided biopsy does not reliably identify dominant cancer location in men with low-risk prostate cancer. <i>BJU International</i> , 2012, 110, 50-55.	1.3	43
5	Regional Variation in Active Surveillance for Low-Risk Prostate Cancer in the US. <i>JAMA Network Open</i> , 2020, 3, e2031349.	2.8	41
6	Management for Prostate Cancer Treatment Related Posterior Urethral and Bladder Neck Stenosis With Stents. <i>Journal of Urology</i> , 2011, 185, 198-203.	0.2	40
7	A once-daily dose of tadalafil for erectile dysfunction: compliance and efficacy. <i>Drug Design, Development and Therapy</i> , 2010, 4, 159.	2.0	32
8	Effects of Initial Gleason Grade on Outcomes during Active Surveillance for Prostate Cancer. <i>European Urology Oncology</i> , 2018, 1, 386-394.	2.6	32
9	Web-Based Physician Ratings for California Physicians on Probation. <i>Journal of Medical Internet Research</i> , 2017, 19, e254.	2.1	32
10	Post-Diagnostic Dietary and Lifestyle Factors and Prostate Cancer Recurrence, Progression, and Mortality. <i>Current Oncology Reports</i> , 2021, 23, 37.	1.8	31
11	The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer. <i>Journal of Urology</i> , 2020, 204, 1222-1228.	0.2	30
12	Perspectives From Authors and Editors in the Biomedical Disciplines on Predatory Journals: Survey Study. <i>Journal of Medical Internet Research</i> , 2019, 21, e13769.	2.1	30
13	The New Surveillance, Epidemiology, and End Results Prostate with Watchful Waiting Database: Opportunities and Limitations. <i>European Urology</i> , 2020, 78, 335-344.	0.9	28
14	Racial distribution of urology workforce in United States in comparison to general population. <i>Translational Andrology and Urology</i> , 2018, 7, 526-534.	0.6	22
15	Mediators of Racial Disparity in the Use of Prostate Magnetic Resonance Imaging Among Patients With Prostate Cancer. <i>JAMA Oncology</i> , 2022, 8, 687.	3.4	20
16	Social Determinants of Appropriate Treatment for Muscle-Invasive Bladder Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1339-1344.	1.1	19
17	Automating the Capture of Structured Pathology Data for Prostate Cancer Clinical Care and Research. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-8.	1.0	17
18	Trends in the Racial and Ethnic Diversity in the US Urology Workforce. <i>Urology</i> , 2022, 162, 9-19.	0.5	16

#	ARTICLE	IF	CITATIONS
19	Stability of a 17-Gene Genomic Prostate Score in Serial Testing of Men on Active Surveillance for Early Stage Prostate Cancer. <i>Journal of Urology</i> , 2019, 202, 696-701.	0.2	16
20	MRI-Based Prostate-Specific Antigen Density Predicts Gleason Score Upgrade in an Active Surveillance Cohort. <i>American Journal of Roentgenology</i> , 2020, 214, 574-578.	1.0	15
21	Serial Prostate Biopsy and Risk of Lower Urinary Tract Symptoms: Results From a Large, Single-institution Active Surveillance Cohort. <i>Urology</i> , 2014, 83, 33-39.	0.5	13
22	Determinants of Guideline-Based Treatment in Patients With cT1 Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, e461-e471.	0.9	13
23	Health Care Delivery for Metastatic Hormone-sensitive Prostate Cancer Across the Globe. <i>European Urology Focus</i> , 2019, 5, 155-158.	1.6	13
24	Diagnostic Accuracy and Prognostic Value of Serial Prostate Multiparametric Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer. <i>European Urology Oncology</i> , 2022, 5, 537-543.	2.6	13
25	Active surveillance for intermediate-risk prostate cancer. <i>Current Opinion in Urology</i> , 2019, 29, 605-611.	0.9	12
26	Disparities in fertility knowledge among women from low and high resource settings presenting for fertility care in two United States metropolitan centers. <i>Fertility Research and Practice</i> , 2020, 6, 15.	4.1	12
27	Multiparametric Magnetic Resonance Imaging Alone is Insufficient to Detect Grade Reclassification in Active Surveillance for Prostate Cancer. <i>European Urology</i> , 2020, 78, 515-517.	0.9	12
28	Benign Prostate Glandular Tissue at Radical Prostatectomy Surgical Margins. <i>Urology</i> , 2013, 82, 154-159.	0.5	11
29	Risk Factors for Biopsy Reclassification over Time in Men on Active Surveillance for Early Stage Prostate Cancer. <i>Journal of Urology</i> , 2020, 204, 1216-1221.	0.2	9
30	The effect of preoperative membranous urethral length on likelihood of postoperative urinary incontinence after robot-assisted radical prostatectomy. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 344-350.	2.0	9
31	Management of intermediate-risk prostate cancer with active surveillance. <i>Current Opinion in Urology</i> , 2017, 27, 231-237.	0.9	8
32	Race modifies survival benefit of guideline-based treatment: Implications for reducing disparities in muscle invasive bladder cancer. <i>Cancer Medicine</i> , 2020, 9, 8310-8317.	1.3	8
33	Active surveillance in intermediate-risk prostate cancer with PSA 10-20 ng/mL: pathological outcome analysis of a population-level database. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 690-693.	2.0	8
34	Androgen Deprivation Therapy and the Risk of Dementia after Treatment for Prostate Cancer. <i>Journal of Urology</i> , 2022, 207, 832-840.	0.2	8
35	Characteristics of Cancer Progression on Serial Biopsy in Men on Active Surveillance for Early-stage Prostate Cancer: Implications for Focal Therapy. <i>European Urology Oncology</i> , 2020, , .	2.6	7
36	The Association Between Race and Frailty in Older Adults Presenting to a Nononcologic Urology Practice. <i>Urology</i> , 2019, 127, 19-23.	0.5	6

#	ARTICLE	IF	CITATIONS
37	What is the Impact of Racial Disparities on Diagnosis and Receipt of Appropriate Mental Health Care Among Urology Patients?. <i>European Urology Focus</i> , 2020, 6, 1155-1157.	1.6	6
38	How Often Does Magnetic Resonance Imaging Detect Prostate Cancer Missed by Transrectal Ultrasound?. <i>European Urology Focus</i> , 2021, 7, 1268-1273.	1.6	6
39	Influence of pelvic lymph node dissection and node-positive disease on biochemical recurrence, secondary treatment, and survival after radical prostatectomy in men with prostate cancer. <i>Prostate</i> , 2021, 81, 102-108.	1.2	6
40	Liposomal Bupivacaine Decreases Postoperative Length of Stay and Opioid Use in Patients Undergoing Radical Cystectomy. <i>Urology</i> , 2021, 149, 168-173.	0.5	6
41	Whom to Treat. <i>Urologic Clinics of North America</i> , 2017, 44, 547-555.	0.8	5
42	A Cross-Sectional Analysis of Barriers Associated With Non-Attendance at a Urology Telehealth Clinic in a Safety-Net Hospital. <i>Urology</i> , 2022, 162, 57-62.	0.5	5
43	Residual Benign Prostate Glandular Tissue after Radical Prostatectomy is Not Associated with the Development of Detectable Postoperative Serum Prostate Specific Antigen. <i>Journal of Urology</i> , 2021, 206, 706-714.	0.2	5
44	Current Use of Imaging after Primary Treatment of Prostate Cancer. <i>Journal of Urology</i> , 2015, 194, 98-104.	0.2	4
45	Acute Bladder Necrosis after Pelvic Arterial Embolization for Pelvic Trauma: Lessons Learned from Two Cases of Immediate Postembolization Bladder Necrosis. <i>Case Reports in Urology</i> , 2016, 2016, 1-4.	0.1	4
46	The Impact of Stone Multiplicity on Surgical Decisions for Patients with Large Stone Burden: Results from ReSKU. <i>Journal of Endourology</i> , 2019, 33, 742-749.	1.1	4
47	Bladder cancer in patients younger than 40 years: outcomes from the National Cancer Database. <i>World Journal of Urology</i> , 2021, 39, 1911-1916.	1.2	4
48	A comparison of stage-specific all-cause mortality between testicular sex cord stromal tumors and germ cell tumors: results from the National Cancer Database. <i>BMC Urology</i> , 2020, 20, 40.	0.6	3
49	The state of our understanding of prostate cancer in sub-Saharan Africa. <i>Cancer</i> , 2021, 127, 4131-4132.	2.0	3
50	The Natural History of Untreated Biopsy Grade Group Progression and Delayed Definitive Treatment for Men on Active Surveillance for Early-Stage Prostate Cancer. <i>Journal of Urology</i> , 2022, 207, 1001-1009.	0.2	3
51	2285 THE COST OF MALE INFERTILITY CARE: HOW MUCH ARE PATIENTS SPENDING?. <i>Journal of Urology</i> , 2013, 189, .	0.2	2
52	Monitoring Prostate Cancer Incidence Trends: Value of Multiple Imputation and Delay Adjustment to Discern Disparities in Stage-specific Trends. <i>European Urology</i> , 2021, 79, 42-43.	0.9	2
53	The Clinical Significance of Multiple Negative Surveillance Prostate Biopsies for Men on Active Surveillance—Does Cancer Vanish or Simply Hide?. <i>Journal of Urology</i> , 2021, 205, 109-114.	0.2	2
54	Natural history of an immediately detectable PSA following radical prostatectomy in a contemporary cohort. <i>Prostate</i> , 2021, 81, 1009-1017.	1.2	2

#	ARTICLE	IF	CITATIONS
55	Ultrasound-Guided Renal Access and Tract Dilatation. Videourology (New Rochelle, N Y), 2017, 31, .	0.1	2
56	Missed opportunity: An intersectional approach to disparities in long-term survival in bladder cancer.. Journal of Clinical Oncology, 2020, 38, 476-476.	0.8	2
57	Health literacy and shared decision making in prostate cancer screening: Equality versus equity. Cancer, 2021, 127, 181-183.	2.0	1
58	MRI-based prostate specific antigen density predicts Gleason score upgrade in an active surveillance cohort.. Journal of Clinical Oncology, 2019, 37, 107-107.	0.8	1
59	Young patients with bladder cancer: Outcomes from the National Cancer Database.. Journal of Clinical Oncology, 2017, 35, 380-380.	0.8	1
60	MP30-10â€fCOMPARISON OF TRUS-TARGETED VS. MRI-TARGETED VS. SYSTEMATIC PROSTATE BIOPSY IN DETECTING PROSTATE CANCER. Journal of Urology, 2019, 201, .	0.2	1
61	Natural history of an immediately detectable PSA following radical prostatectomy: A description of a contemporary cohort.. Journal of Clinical Oncology, 2020, 38, 356-356.	0.8	1
62	The Clinical Applications of Tissue Biomarkers in Prostate Cancer. SociÃ©tÃ© Internationale D'urologie Journal, 2020, 1, 23-29.	0.2	1
63	Translating Patient-Centered Research into Educational Resources to Address Racial Inequities in Prostate Cancer. Journal of Urology, 2022, 207, 496-497.	0.2	1
64	38 PROSTATE CANCER TREATMENT-RELATED POSTERIOR URETHRAL STRICTURES MANAGED WITH UROLUMEÂ® STENTS. Journal of Urology, 2010, 183, .	0.2	0
65	2118 TRANSRECTAL ULTRASOUND GUIDED BIOPSY DOES NOT IDENTIFY DOMINANT PROSTATE CANCER LOCATION RELIABLY. Journal of Urology, 2011, 185, .	0.2	0
66	367 PROSTATE CANCER IN APICAL SKELETAL MUSCLE OF RADICAL PROSTATECTOMY SPECIMENS IS NOT ASSOCIATED WITH BIOCHEMICAL RECURRENCE. Journal of Urology, 2012, 187, .	0.2	0
67	1446 IMPACT OF SERIAL PROSTATE BIOPSIES ON SEXUAL FUNCTION IN MEN ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER. Journal of Urology, 2012, 187, .	0.2	0
68	1445 IMPACT OF SERIAL PROSTATE BIOPSIES ON LOWER URINARY TRACT SYMPTOMS IN MEN ON ACTIVE SURVEILLANCE FOR PROSTATE CANCER. Journal of Urology, 2012, 187, .	0.2	0
69	MP91-19 FINANCIAL BURDENS OF FERTILITY CARE: HOW TREATMENT COSTS IMPACT FINANCIAL DIFFICULTY. Journal of Urology, 2016, 195, .	0.2	0
70	Cystoscopic Evaluation of Bladder Leiomyoma. Urology, 2017, 106, e1-e2.	0.5	0
71	Urinary Diversion for Incontinence and Voiding Dysfunction in Cancer Survivors: a Critical Review of the Literature. Current Bladder Dysfunction Reports, 2017, 12, 167-173.	0.2	0
72	MP10-13 IMPACT OF HISTOLOGIC SUBTYPE ON BLADDER CANCER OUTCOME. Journal of Urology, 2017, 197, .	0.2	0

#	ARTICLE	IF	CITATIONS
73	PD28-12 EFFECTS OF INITIAL GLEASON GRADE ON OUTCOMES DURING ACTIVE SURVEILLANCE FOR PROSTATE CANCER. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
74	MP96-10 INITIAL VALIDATION OF AUTOMATED DATA EXTRACTION METHODS IN UROLOGIC ONCOLOGY PRACTICE. <i>Journal of Urology</i> , 2017, 197, .	0.2	0
75	Young Patients with Bladder Cancer: Outcomes from the National Cancer Database. <i>Journal of the American College of Surgeons</i> , 2017, 225, S211.	0.2	0
76	EDITORIAL COMMENT. <i>Urology</i> , 2021, 148, 209-210.	0.5	0
77	Mediators of racial disparity in the use of prostate MRI.. <i>Journal of Clinical Oncology</i> , 2021, 39, 6554-6554.	0.8	0
78	Abstract 686: Longitudinal analysis of the indirect burden of prostate cancer management on paid and unpaid work: Data from CaPSURE database. <i>Cancer Research</i> , 2021, 81, 686-686.	0.4	0
79	MP03-13â€fTHE LONG-TERM INCIDENCE OF COMPLICATIONS ASSOCIATED WITH RADIOTHERAPY FOR PROSTATE CANCER. <i>Journal of Urology</i> , 2021, 206, .	0.2	0
80	MP24-06â€fCUMULATIVE ANDROGEN DEPRIVATION THERAPY EXPOSURE FOR PROSTATE CANCER IS ASSOCIATED WITH AN INCREASED RISK OF DEMENTIA. <i>Journal of Urology</i> , 2021, 206, .	0.2	0
81	PD08-10â€fLONG-TERM BOWEL AND URINARY HEALTH-RELATED QUALITY OF LIFE AFTER PRIMARY AND SALVAGE RADIATION TREATMENT FOR PROSTATE CANCER: RESULTS FROM THE CaPSURE REGISTRY. <i>Journal of Urology</i> , 2021, 206, .	0.2	0
82	Impact of histologic subtype on bladder cancer outcome.. <i>Journal of Clinical Oncology</i> , 2017, 35, 391-391.	0.8	0
83	Active Surveillance in African-Americans. , 2018, , 53-58.		0
84	Determinants of guideline-based treatment in patients with cT1 bladder cancer.. <i>Journal of Clinical Oncology</i> , 2018, 36, e16518-e16518.	0.8	0
85	Cribriform pattern, Genomic Prostate Score, and adverse pathology at radical prostatectomy in a cohort of prostate cancer patients initially on active surveillance.. <i>Journal of Clinical Oncology</i> , 2019, 37, 88-88.	0.8	0
86	PD40-01â€f18-YEAR PROSTATE CANCER-SPECIFIC MORTALITY AFTER PROSTATECTOMY, BRACHYTHERAPY, EXTERNAL BEAM RADIATION THERAPY, HORMONAL THERAPY, OR MONITORING FOR LOCALIZED PROSTATE CANCER. <i>Journal of Urology</i> , 2019, 201, .	0.2	0
87	18-year prostate cancer-specific mortality after prostatectomy, brachytherapy, external beam radiation therapy, hormonal therapy, or monitoring for localized prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 300-300.	0.8	0
88	Abstract D123: The intersection of race and delivery of guideline-based: How treatment disparities drive racial disparities in muscle-invasive bladder cancer. , 2020, , .		0
89	Abstract D124: Racial differences in adverse pathology among men with prostate cancer at time of radical prostatectomy. , 2020, , .		0
90	Reply by Authors. <i>Journal of Urology</i> , 2020, 204, 1221-1221.	0.2	0

#	ARTICLE	IF	CITATIONS
91	Assessing focality of dominant tumor on serial biopsy in an active surveillance cohort: Implications for focal therapy.. Journal of Clinical Oncology, 2020, 38, 352-352.	0.8	0
92	Influence of node-positive disease after radical prostatectomy on biochemical recurrence and oncologic outcomes in men with prostate cancer.. Journal of Clinical Oncology, 2020, 38, 306-306.	0.8	0
93	Risk factors which predict biopsy upgrading over time in active surveillance for prostate cancer.. Journal of Clinical Oncology, 2020, 38, 290-290.	0.8	0
94	PD13-08â€fANALYZING THE ASSOCIATION BETWEEN EXPOSURE TO ANDROGEN DEPRIVATION THERAPY AND THE ONSET OF ALZHEIMER'S DISEASE AND DEMENTIA IN MEN WITH PROSTATE CANCER. Journal of Urology, 2020, 203, .	0.2	0
95	MP23-13â€fDEFINING INTERMEDIATE-RISK PROSTATE CANCER SUITABLE FOR ACTIVE SURVEILLANCE WITH PSA 10-20NG/ML: PATHOLOGICAL OUTCOME ANALYSIS OF A POPULATION-LEVEL DATASET. Journal of Urology, 2020, 203, .	0.2	0
96	PD62-10â€fASSESSING FOCALITY OF DOMINANT TUMOR ON SERIAL BIOPSY IN AN ACTIVE SURVEILLANCE COHORT - IMPLICATIONS FOR FOCAL THERAPY. Journal of Urology, 2020, 203, .	0.2	0
97	EDITORIAL COMMENT. Urology, 2022, 162, 26.	0.5	0